The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Thymus Epithelial TumorProton RadiotherapyRadiation Toxicity
Interventions
RADIATION

Proton radiotherapy

Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.

OTHER

combined platinum based chemotherapy

combined platinum based chemotherapy

Trial Locations (1)

201513

RECRUITING

Shanghai Proton and Heavy Ion Center, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Jian Chen

OTHER

NCT06311968 - The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor | Biotech Hunter | Biotech Hunter